Category
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Stem Cells & Wnt
- Hippo
- Ubiquitin
- Neuronal Signaling
- NF-κB
- GPCR & G Protein
- Endocrinology & Hormones
- Transmembrane Transporters
- Metabolism
- Proteases
- Microbiology
- Others
Archives
ALK
Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer
12 views | Dec 23 2020
Hedvig Elfving et al. found that the presence of NTRK fusion genes in non-small cell lung cancer was exceedingly rare. The use of the immunohistochemical NTRK assay would result in a small number of false positive cases. [Read the Full Post]
Clinicopathologic, Genomic, and Protein Expression Characterization of 356 ROS1 Fusion Driven Solid Tumors Cases
13 views | Dec 22 2020
Richard S P Huang et al. characterized a large cohort of ROS1 fusionpos NSCLC and non-NSCLC solid tumors and discovered 10 novel ROS1 fusions. [Read the Full Post]
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
0 views | Nov 24 2020
Diana Cervantes-Madrid et al. showed that repotrectinib was capable of inhibiting signaling activity of a range of ALK mutant variants found in neuroblastoma patients and importantly it exhibited strong antitumor effects in a xenograft model of neuroblastoma. [Read the Full Post]
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
18 views | Nov 23 2020
Kartik Sehgal et al. described cases of advanced ROS1-rearranged lung cancer receiving crizotinib, entrectinib, and/or lorlatinib in first and later line treatment settings to dissect the current state of evidence supporting management decisions for these patients. [Read the Full Post]
Alectinib-Associated Perforated Duodenal Ulcer
21 views | Nov 14 2020
Maximilian J Hochmair et al. found that later-line lorlatinib treatment could induce sustained responses in patients with advanced ALK- and ROS1-positive lung cancer. [Read the Full Post]
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
49 views | Sep 13 2020
Tomohiro Sato et al. indicated the existence of the additional hydrogen bond via water molecules restricting the attachment point in the pyrazole scaffold [Read the Full Post]
Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
75 views | Aug 23 2020
Abhay Singh et al. provided a summary of the clinical development of crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib and highlighted current management paradigms, current and evolving clinical information, emerging clinical decision-making and sequencing of therapy in advanced, metastatic, or recurrent ALK-positive NSCLC. [Read the Full Post]
Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
85 views | Aug 04 2020
Kyoung-Ho Pyo et al. found that ALK-positive tumors progressing on ceritinib was not immunogenic enough to respond to immune checkpoint inhibitors. [Read the Full Post]
STMN1 Upregulation Mediates Hepatocellular Carcinoma and Hepatic Stellate Cell Crosstalk to Aggravate Cancer by Triggering the MET Pathway
135 views | Jun 15 2020
Rui Zhang et al. suggested that STMN1 may be used as a potential marker to identify patients who may benefit from MET inhibitor treatment. [Read the Full Post]
Real-World Treatment Patterns and Progression-Free Survival Associated With Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer
129 views | Jun 08 2020
Mohammad Jahanzeb et al. found that median rwPFS in patients with advanced ALK+ NSCLC was < 8 months for first- and second-line ALK TKI therapy and was even shorter in patients with brain metastasis, highlighting the need for more effective treatments in this patient population. [Read the Full Post]
